Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Should Outsource R&D To Manage Drug Development Costs, HGS CEO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Nearly all aspects of the drug development process can be done in other countries at substantial savings, Human Genome Sciences' Haseltine says. Outsourcing could reduce costs by up to two-thirds and allow greater flexibility, he maintains.
Advertisement

Related Content

GSK Predicts Outsourcing R&D To “Low-Cost” Countries Could Save $200 Mil.
GSK Predicts Outsourcing R&D To “Low-Cost” Countries Could Save $200 Mil.
HGS To Focus On "Core Pipeline" As Part Of Cost Reduction Plan; CEO Steps Down
HGS To Focus On "Core Pipeline" As Part Of Cost Reduction Plan; CEO Steps Down

Topics

Advertisement
UsernamePublicRestriction

Register

PS059441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel